Hungary
VRG Therapeutics, founded in 2023 and headquartered in Hungary, is making strides in the biotechnology sector with its innovative approach to drug discovery. The company operates at the intersection of technology and biology, leveraging an AI-powered miniprotein R&D platform to transform the development of next-generation therapeutics. The platform is designed to tackle previously undruggable targets, aiming to unlock new mechanisms of action and cure diseases that have long challenged medical science.
In a significant milestone, VRG Therapeutics secured a €5.00M Series A investment on 01 August 2023, backed by Széchenyi Alapok - Széchenyi Funds and The Vascular Group. This investment underscores confidence in their pioneering platform and prospective disruptive impact within the biotech industry. As a newly founded company, VRG Therapeutics presents a compelling growth opportunity by bridging AI and biotechnology for innovative therapeutic solutions.
